NO20005186L - Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor - Google Patents

Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor

Info

Publication number
NO20005186L
NO20005186L NO20005186A NO20005186A NO20005186L NO 20005186 L NO20005186 L NO 20005186L NO 20005186 A NO20005186 A NO 20005186A NO 20005186 A NO20005186 A NO 20005186A NO 20005186 L NO20005186 L NO 20005186L
Authority
NO
Norway
Prior art keywords
enhancement
administration
immune responses
mediated immune
protein mediated
Prior art date
Application number
NO20005186A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005186D0 (no
Inventor
Stephen D Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of NO20005186D0 publication Critical patent/NO20005186D0/no
Publication of NO20005186L publication Critical patent/NO20005186L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO20005186A 1998-04-17 2000-10-16 Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor NO20005186L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8216698P 1998-04-17 1998-04-17
PCT/US1999/008376 WO1999053958A2 (en) 1998-04-17 1999-04-16 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor

Publications (2)

Publication Number Publication Date
NO20005186D0 NO20005186D0 (no) 2000-10-16
NO20005186L true NO20005186L (no) 2000-12-14

Family

ID=22169464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005186A NO20005186L (no) 1998-04-17 2000-10-16 Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor

Country Status (16)

Country Link
US (1) US20040033210A1 (cs)
EP (1) EP1071469A2 (cs)
JP (1) JP2002512204A (cs)
CN (1) CN1305387A (cs)
AU (1) AU758851B2 (cs)
BR (1) BR9909677A (cs)
CA (1) CA2328081A1 (cs)
CZ (1) CZ20003817A3 (cs)
HK (1) HK1038881A1 (cs)
HU (1) HUP0101343A3 (cs)
MX (1) MXPA00010151A (cs)
NO (1) NO20005186L (cs)
PL (1) PL343486A1 (cs)
RU (1) RU2217168C2 (cs)
WO (1) WO1999053958A2 (cs)
ZA (1) ZA200005477B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
ATE462725T1 (de) * 1998-08-25 2010-04-15 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU6227400A (en) * 1999-07-26 2001-02-13 Childrens Hospital Los Angeles Research Institute Fenretinide increases antibody cellular toxicity
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
JP5390055B2 (ja) 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
DK1490480T3 (en) * 2002-03-15 2016-04-11 Univ North Carolina PRIMITIVE AND PROXIMAL Liver Stem Cells
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
PT1699822E (pt) * 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1966238B1 (en) * 2005-12-30 2012-04-25 Merck Patent GmbH Interleukin-12p40 variants with improved stability
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2561888A1 (en) 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
DE3812605A1 (de) * 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
CA2258593A1 (en) * 1996-07-02 1998-01-08 Abraham Nudelman Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Also Published As

Publication number Publication date
HUP0101343A3 (en) 2003-10-28
HUP0101343A2 (hu) 2001-08-28
AU758851B2 (en) 2003-04-03
MXPA00010151A (es) 2002-08-06
NO20005186D0 (no) 2000-10-16
US20040033210A1 (en) 2004-02-19
CN1305387A (zh) 2001-07-25
PL343486A1 (en) 2001-08-27
JP2002512204A (ja) 2002-04-23
BR9909677A (pt) 2000-12-19
CA2328081A1 (en) 1999-10-28
EP1071469A2 (en) 2001-01-31
ZA200005477B (en) 2001-11-20
AU3566499A (en) 1999-11-08
RU2217168C2 (ru) 2003-11-27
CZ20003817A3 (cs) 2002-08-14
WO1999053958A3 (en) 1999-12-02
HK1038881A1 (zh) 2002-04-04
WO1999053958A2 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
NO20005186D0 (no) Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor
NO20035426L (no) Fremgangsmate ved administrering av anti-TNF-D-antistoff
DE60127894D1 (de) Verminderung der Rissneigung bei Flanschverbindungen
EP1507555A4 (en) INTRODUCTION ANTIGEN-SPECIFIC IMMUNOLOGICAL TOLERANCE
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
NO20023788L (no) Antistoff som binder humant interleukin-18 samt fremgangsmater ved fremstilling og anvendelse derav
DE69627179D1 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
ATE172199T1 (de) Proteinkinase-c-inhibitor
NO20001648L (no) FremgangsmÕter og mellomprodukter for fremstilling av anti- cancerforbindelser
EP0692536A3 (en) Protein that induces interferon gamma production and monoclonal antibodies against it
DK124588A (da) Doseringsformer med forsinket frigoerelse
EP1503795A4 (en) USE OF STRESS PROTEINS TO IMPROVE THE EFFICIENCY OF THERAPEUTIC ANTIBODIES
EP1240191A4 (en) ANTIGENIC COMPOSITION OF P. GINGIVALIS
AU2002232447A1 (en) Method of enhancing lymphocyte-mediated immune responses
DE60110232D1 (de) Neue verwendung von lipase-inhibitoren
ID22650A (id) Penggunaan penghambat-penghambat lipase usus lambung
DK38293D0 (da) Fremstilling af proteiner
AR028261A1 (es) Inhibidores triciclicos de la proteina quinasa
MXPA03006817A (es) Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
ID23187A (id) Bentuk bentuk dosis sertralina lepas tunda
FI950888L (fi) Menetelmä K-vitamiinista riippuvaisten proteiinien eristämiseksi ja puhdistamiseksi
DK0912612T3 (da) Forenklet fremstilling af bispecifikke antistoffragmenter
DK112988A (da) Rnase l inhibitor som markoer for virusinfektioner
EE200300570A (et) Imidasotriasinoonide derivaadid ja nende kasutamine põletikuliste protsesside ja/või immuunhaigustevastu
DE60118528D1 (de) Häertung von entwachsungsreaktor durch rückführung schwerer reaktionsprodukte

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application